Baillie Gifford & Co. Cuts Stock Position in Tempus AI, Inc. $TEM

Baillie Gifford & Co. cut its position in shares of Tempus AI, Inc. (NASDAQ:TEM) by 19.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,692,441 shares of the company’s stock after selling 2,401,588 shares during the quarter. Baillie Gifford & Co. owned approximately 0.06% of Tempus AI worth $782,277,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. AQR Capital Management LLC purchased a new stake in Tempus AI in the second quarter worth approximately $54,020,000. Geode Capital Management LLC boosted its stake in shares of Tempus AI by 411.4% in the 2nd quarter. Geode Capital Management LLC now owns 649,420 shares of the company’s stock valued at $41,264,000 after purchasing an additional 522,443 shares in the last quarter. Marex Group plc bought a new position in shares of Tempus AI during the 2nd quarter valued at $26,620,000. Gilder Gagnon Howe & Co. LLC grew its holdings in shares of Tempus AI by 1,747.6% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 413,081 shares of the company’s stock valued at $26,247,000 after purchasing an additional 390,723 shares during the last quarter. Finally, Patient Capital Management LLC purchased a new position in Tempus AI in the 2nd quarter worth $24,693,000. Institutional investors own 24.22% of the company’s stock.

Insider Buying and Selling

In other Tempus AI news, EVP Erik Phelps sold 1,302 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $67.42, for a total value of $87,780.84. Following the completion of the transaction, the executive vice president directly owned 89,280 shares in the company, valued at approximately $6,019,257.60. This represents a 1.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jennifer A. Doudna sold 676 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $75.55, for a total transaction of $51,071.80. Following the completion of the sale, the director directly owned 23,952 shares of the company’s stock, valued at approximately $1,809,573.60. This represents a 2.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 932,832 shares of company stock valued at $71,184,024 over the last three months. Insiders own 26.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on TEM shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research note on Wednesday, October 8th. Morgan Stanley increased their target price on Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, December 1st. BTIG Research raised their price target on Tempus AI from $96.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, November 25th. Needham & Company LLC lifted their price target on Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Finally, JPMorgan Chase & Co. dropped their price objective on Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $87.20.

Tempus AI Stock Down 4.4%

NASDAQ TEM opened at $65.32 on Friday. Tempus AI, Inc. has a 1 year low of $36.22 and a 1 year high of $104.32. The stock has a market capitalization of $11.62 billion, a PE ratio of -54.89 and a beta of 5.22. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12. The business’s 50-day moving average is $68.87 and its 200 day moving average is $73.68.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05. The business had revenue of $334.21 million during the quarter, compared to analysts’ expectations of $328.89 million. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The business’s revenue was up 84.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.46) EPS. Sell-side analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.